Multiple myeloma
Research activity is concentrated in newly diagnosed multiple myeloma, relapsed/refractory multiple myeloma, and first-line treatment settings, with additional interest in patients who have received prior lenalidomide– and proteasome inhibitor-based therapy. Studies also address transplant-ineligible disease and treatment sequencing across early and later lines of care.
- Newly diagnosed multiple myeloma
- Relapsed/refractory multiple myeloma
- Transplant-ineligible patients
- Lenalidomide-refractory disease
Several trials focus on antibody-based and combination approaches in myeloma care, including settings with severe renal impairment and treatment-naïve patients requiring tailored therapeutic options.
Plasma cell disorders
Beyond typical myeloma populations, the sponsor supports research in primary plasma cell leukemia, reflecting interest in aggressive plasma cell dyscrasias and frontline disease control. This includes studies aimed at improving outcomes in rare and high-risk hematologic malignancies within the plasma cell spectrum.
- Primary plasma cell leukemia
- High-risk plasma cell malignancies
- Frontline disease management
The portfolio extends to treatment strategies that combine established hematologic agents with newer targeted and immune-directed therapies in difficult-to-treat plasma cell disease.
Acute myeloid leukaemia
Research also includes acute myeloid leukaemia, with attention to FLT3-ITD-positive disease and measurable residual disease eradication. This indicates involvement in molecularly defined leukemia care and response optimization in the post-treatment setting.
- Acute myeloid leukaemia
- FLT3-ITD mutation
- Measurable residual disease
The leukemia program reflects a focus on precision-oriented hematology, with therapeutic interest in mutation-directed treatment for residual disease control.
Immune thrombocytopenia
The sponsor funds research in primary immune thrombocytopenia, supporting therapeutic evaluation in an autoimmune bleeding disorder characterized by low platelet counts. This area adds an immune-mediated hematology dimension to the broader oncology-focused portfolio.
- Primary immune thrombocytopenia
- Autoimmune platelet disorders
- Bleeding risk management
Interest in this condition highlights attention to both malignant and non-malignant hematologic diseases requiring specialized medical management.
